Article Sidebar
Date Published:
16/04/2025
Abstract Views: 91
Views PDF: 29
Views PDF: 29
Issue
Section
Scientific research
How to Cite
Nguyen, T. N. H., Dang, D. L., Nguyen, T. Q. C., Vu, T. T. H., Phan, T. H. N., & Duong, H. Q. (2025). OVERVIEW OF TESTING METHODS TO DETECT ER AND PR IN BREAST CANCER PATIENTS IN THE WORLD AND VIETNAM IN THE PERIOD 2010-2024. Vietnam Journal of Infectious Diseases, 1(49), 120-128. https://doi.org/10.59873/vjid.v1i49.456
OVERVIEW OF TESTING METHODS TO DETECT ER AND PR IN BREAST CANCER PATIENTS IN THE WORLD AND VIETNAM IN THE PERIOD 2010-2024
Main Article Content
Abstract
Objectives: To describe testing methods to detect ER and PR in breast cancer patients in the world and in VietNam in the period 2010 - 2024.
Objects and methods: Synthesize and analyze studies and reports on testing methods to detect ER, PR in breast cancer patients in the period 2010 - 2024 in the world and in Vietnam on major online medical databases such as: Medline/Pubmed, Cochrane library, Google Scholar and GLOBOCAN; Domestic medical journals; use Zotero 7.0 software to manage and cite collected documents.
Results: 22 studies and reports from around the world and in Vietnam were selected for the study, including
14 documents from around the world and 8 documents from Vietnam. In the period 2010 - 2024, in the world, the most popular testing method to detect ER, PR in breast cancer patients is Immunohistochemistry, followed by molecular biological techniques such as RT-qPCR and gene sequencing. In Vietnam, only Immunohistochemistry is used to detect ER, PR in breast cancer patients.
Conclusions: During the period 2010 - 2024; In the world, there are 3 testing methods to detect ER and PR in breast cancer patients including Immunohistochemistry, RT-qPCR and gene sequencing, of which Immunohistochemistry is the most popular method; In Vietnam, Immunohistochemistry is the only testing method to detect ER and PR in breast cancer patients.
Article Details
Keywords
Breast cancer, estrogen (ER), progesterone (PR), diagnosis, Vietnam, world
References
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834.
2. Li Y, Yang D, Yin X, et al. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. JAMA Netw Open. 2020;3(1):e1918160.
doi:10.1001/jamanetworkopen.2019.18160.
3. Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023;24(7):6834. doi:10.3390/ijms24076834
4. Vũ HTN, Quỳnh LTN, Nhung NĐH, Vân TTN. Chi phí - hiệu quả của các liệu pháp nội tiết trong điều trị ung thư vú: Nghiên cứu tổng quan hệ thống. Tạp chí Y học Việt Nam. 2023;522(1). doi:10.51298/
vmj.v522i1.4256.
5. Do Quyen PT, Viet Cuong N. Đánh giá hiệu quả điều trị của liệu pháp nội tiết bổ trợ trong ung thư vú. J Clin Med - Hue Cent Hosp. 2022;(82). doi:10.38103/jcmhch.82.14.
6. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439. doi:10.1016/S1470-2045(15)00613-0.
7. Finitsis DJ, Vose BA, Mahalak JG, Salner AL. Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta-analysis. Psychooncology. 2019;28(2):255-263. doi:10.1002/pon.4959.
8. Zelnak AB, O’Regan RM. Optimizing Endocrine Therapy for Breast Cancer. J Natl Compr Cancer Netw JNCCN. 2015;13(8):e56-64. doi:10.6004/jnccn.2015.0125.
9. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321(3):288-300. doi:10.1001/jama.2018.19323.
10. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and
progesterone receptors in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(16):2784-2795.doi:10.1200/JCO.2009.25.6529.
11.Vani K, Sompuram SR, Schaedle AK, Balasubramanian A, Bogen SA. Analytic Response Curves of Clinical Breast Cancer IHC Tests. J Histochem Cytochem. 2017;65(5):273-283. doi:10.1369/0022155417694869.
12. Wu NC, Wong W, Ho KE, et al. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on
an automated, broadly deployed diagnostic platform. Breast Cancer Res Treat. 2018;172(2):327-338. doi:10.1007/s10549-018-4889-5.
13. Abubakar M, Figueroa J, Ali HR, et al. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Mod
Pathol. 2019;32(9):1244-1256. doi:10.1038/s41379-019-0270-4.
14. Ross DS, Zehir A, Brogi E, et al. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Mod Pathol.
2019;32(1):81-87. doi:10.1038/s41379-018-0116-5.
15. Purdie CA, Quinlan P, Jordan LB, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014;110(3):565-572. doi:10.1038/
bjc.2013.756.
16. Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases. Breast Cancer Basic Clin Res. 2013;7:23-34. doi:10.4137/BCBCR.S10701.
17. Janeva S, Parris TZ, Nasic S, et al. Comparison of breast cancer surrogate subtyping using a closedsystem RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens. BMC Cancer. 2021;21(1):439. doi:10.1186/s12885-021-08171-2.
18. Janeva S, Krabbe E, Parris TZ, et al. Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer. Breast Cancer Res. 2023;25(1):36. doi:10.1186/s13058-
023-01632-5.
19. Kao KJ, Chang KM, Hsu HC, Huang AT. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer. 2011;11(1):143.
doi:10.1186/1471-2407-11-143.
20. Chen L, Chen Y, Xie Z, et al. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer. Breast Cancer Res Treat.
2022;194(3):517-529. doi:10.1007/s10549-022-06649-6.
21. Dodiya H, Patel A, Patel D, Kaushal A, Vijay DG. Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India. Indian J Clin Biochem.
2013;28(4):403-409. doi:10.1007/s12291-012-0294-8.
22. Jung M, Song SG, Cho SI, et al. Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
Breast Cancer Res. 2024;26(1):31. doi:10.1186/s13058-024-01784-y.
23. At S, Ns HM, Am E, S B, Ej K, Aa M. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series. BMC Cancer. 2017;17(1). doi:10.1186/
s12885-017-3805-4.
24. Văn Chủ N. Sự bộc lộ thụ thể androgen và estrogen trong ung thư biểu mô tuyến vú xâm nhập. Tạp chí Y học Việt Nam. 2021;501(1). doi:10.51298/vmj.v501i1.428.
25. Dang CT, Phan TTT, Tran ND, Ngo CS, Vo THV. Study on relation between traditional prognosis factors and hormone receptors status, KI-67, her2 in invasive breast carcinomA. J Med Pharm. Published online
February 2017:70-76. doi:10.34071/jmp.2017.1.11.
26. Tiên NPT, Hùng TA, Mão NV và cộng sự. Nghiên cứu phân nhóm phân tử và mối liên quan với các đặc điểm giải phẫu bệnh của bệnh nhân ung thư vú Việt Nam và Ý. Accessed September 18, 2024. http://jmp.huemed-univ.edu.vn/BBao/2023/3/PDF_2023m03d010_16_11_33.pdf.
27. Nguyễn VC, Chu TT. Mối liên quan giữa thang điểm ihc4 và típ phân tử của ung thư vú có thụ thể nội tiết dương tính giai đoạn I-II. Tạp chí Y học Việt Nam. 2021;500(1). doi:10.51298/vmj.v500i1.298.
28. Nguyen Phuong Thao T, Tran Anh H, Nguyen Van M, et al. Study on molecular subtypes and correlation between molecular subtypes and histopathological features in invasive breast cancer. J Med Pharm.
Published online October 2022:171-177. doi:10.34071/jmp.2022.5.25.
29. cộng C thông tin T tâm T tin T viện TĐ học Y tế công. Đánh giá kết quả nhuộm hóa mô miễn dịch thủ công so với nhuộm tự động thụ thể estrogen trong ung thư vú. library.huph.edu.vn/. Accessed September
18, 2024. https://library.huph.edu.vn:443/tai-lieu-chi-tiet/4d3cbb08145d4367a9c7e8a8a33c9378.
html?id=4d3cbb08145d4367a9c7e8a8a33c9378.
30. Tuân HV, Phương ĐM, Hương NT. Mối liên quan giữa đa hình rs1801320 gen rad51 với tình trạng thụ thể ER, PR và her-2 ở bệnh nhân ung thư vú. Tạp chí Y học Việt Nam. 2024;541(3). doi:10.51298/vmj.
v541i3.10902.
31. Lympho bào xâm nhập u và mối liên quan với một số đặc điểm mô bệnh học trong ung thư biểu mô vú bộ ba âm tính. Accessed September 18, 2024. https://tapchinghiencuuyhoc.vn/index.php/tcncyh/article/
view/2478/1662.
2. Li Y, Yang D, Yin X, et al. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. JAMA Netw Open. 2020;3(1):e1918160.
doi:10.1001/jamanetworkopen.2019.18160.
3. Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023;24(7):6834. doi:10.3390/ijms24076834
4. Vũ HTN, Quỳnh LTN, Nhung NĐH, Vân TTN. Chi phí - hiệu quả của các liệu pháp nội tiết trong điều trị ung thư vú: Nghiên cứu tổng quan hệ thống. Tạp chí Y học Việt Nam. 2023;522(1). doi:10.51298/
vmj.v522i1.4256.
5. Do Quyen PT, Viet Cuong N. Đánh giá hiệu quả điều trị của liệu pháp nội tiết bổ trợ trong ung thư vú. J Clin Med - Hue Cent Hosp. 2022;(82). doi:10.38103/jcmhch.82.14.
6. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439. doi:10.1016/S1470-2045(15)00613-0.
7. Finitsis DJ, Vose BA, Mahalak JG, Salner AL. Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta-analysis. Psychooncology. 2019;28(2):255-263. doi:10.1002/pon.4959.
8. Zelnak AB, O’Regan RM. Optimizing Endocrine Therapy for Breast Cancer. J Natl Compr Cancer Netw JNCCN. 2015;13(8):e56-64. doi:10.6004/jnccn.2015.0125.
9. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321(3):288-300. doi:10.1001/jama.2018.19323.
10. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and
progesterone receptors in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(16):2784-2795.doi:10.1200/JCO.2009.25.6529.
11.Vani K, Sompuram SR, Schaedle AK, Balasubramanian A, Bogen SA. Analytic Response Curves of Clinical Breast Cancer IHC Tests. J Histochem Cytochem. 2017;65(5):273-283. doi:10.1369/0022155417694869.
12. Wu NC, Wong W, Ho KE, et al. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on
an automated, broadly deployed diagnostic platform. Breast Cancer Res Treat. 2018;172(2):327-338. doi:10.1007/s10549-018-4889-5.
13. Abubakar M, Figueroa J, Ali HR, et al. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Mod
Pathol. 2019;32(9):1244-1256. doi:10.1038/s41379-019-0270-4.
14. Ross DS, Zehir A, Brogi E, et al. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Mod Pathol.
2019;32(1):81-87. doi:10.1038/s41379-018-0116-5.
15. Purdie CA, Quinlan P, Jordan LB, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014;110(3):565-572. doi:10.1038/
bjc.2013.756.
16. Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases. Breast Cancer Basic Clin Res. 2013;7:23-34. doi:10.4137/BCBCR.S10701.
17. Janeva S, Parris TZ, Nasic S, et al. Comparison of breast cancer surrogate subtyping using a closedsystem RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens. BMC Cancer. 2021;21(1):439. doi:10.1186/s12885-021-08171-2.
18. Janeva S, Krabbe E, Parris TZ, et al. Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer. Breast Cancer Res. 2023;25(1):36. doi:10.1186/s13058-
023-01632-5.
19. Kao KJ, Chang KM, Hsu HC, Huang AT. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer. 2011;11(1):143.
doi:10.1186/1471-2407-11-143.
20. Chen L, Chen Y, Xie Z, et al. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer. Breast Cancer Res Treat.
2022;194(3):517-529. doi:10.1007/s10549-022-06649-6.
21. Dodiya H, Patel A, Patel D, Kaushal A, Vijay DG. Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India. Indian J Clin Biochem.
2013;28(4):403-409. doi:10.1007/s12291-012-0294-8.
22. Jung M, Song SG, Cho SI, et al. Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
Breast Cancer Res. 2024;26(1):31. doi:10.1186/s13058-024-01784-y.
23. At S, Ns HM, Am E, S B, Ej K, Aa M. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series. BMC Cancer. 2017;17(1). doi:10.1186/
s12885-017-3805-4.
24. Văn Chủ N. Sự bộc lộ thụ thể androgen và estrogen trong ung thư biểu mô tuyến vú xâm nhập. Tạp chí Y học Việt Nam. 2021;501(1). doi:10.51298/vmj.v501i1.428.
25. Dang CT, Phan TTT, Tran ND, Ngo CS, Vo THV. Study on relation between traditional prognosis factors and hormone receptors status, KI-67, her2 in invasive breast carcinomA. J Med Pharm. Published online
February 2017:70-76. doi:10.34071/jmp.2017.1.11.
26. Tiên NPT, Hùng TA, Mão NV và cộng sự. Nghiên cứu phân nhóm phân tử và mối liên quan với các đặc điểm giải phẫu bệnh của bệnh nhân ung thư vú Việt Nam và Ý. Accessed September 18, 2024. http://jmp.huemed-univ.edu.vn/BBao/2023/3/PDF_2023m03d010_16_11_33.pdf.
27. Nguyễn VC, Chu TT. Mối liên quan giữa thang điểm ihc4 và típ phân tử của ung thư vú có thụ thể nội tiết dương tính giai đoạn I-II. Tạp chí Y học Việt Nam. 2021;500(1). doi:10.51298/vmj.v500i1.298.
28. Nguyen Phuong Thao T, Tran Anh H, Nguyen Van M, et al. Study on molecular subtypes and correlation between molecular subtypes and histopathological features in invasive breast cancer. J Med Pharm.
Published online October 2022:171-177. doi:10.34071/jmp.2022.5.25.
29. cộng C thông tin T tâm T tin T viện TĐ học Y tế công. Đánh giá kết quả nhuộm hóa mô miễn dịch thủ công so với nhuộm tự động thụ thể estrogen trong ung thư vú. library.huph.edu.vn/. Accessed September
18, 2024. https://library.huph.edu.vn:443/tai-lieu-chi-tiet/4d3cbb08145d4367a9c7e8a8a33c9378.
html?id=4d3cbb08145d4367a9c7e8a8a33c9378.
30. Tuân HV, Phương ĐM, Hương NT. Mối liên quan giữa đa hình rs1801320 gen rad51 với tình trạng thụ thể ER, PR và her-2 ở bệnh nhân ung thư vú. Tạp chí Y học Việt Nam. 2024;541(3). doi:10.51298/vmj.
v541i3.10902.
31. Lympho bào xâm nhập u và mối liên quan với một số đặc điểm mô bệnh học trong ung thư biểu mô vú bộ ba âm tính. Accessed September 18, 2024. https://tapchinghiencuuyhoc.vn/index.php/tcncyh/article/
view/2478/1662.